OCUPRESS

What it isNon-selective beta blocker eye drop with intrinsic sympathomimetic activity; glaucoma.
Why this onePartial agonism gives a slightly better lipid and heart-rate profile than timolol.
What limits itSystemic beta blockade still occurs. Avoid in asthma and heart block.
Animated chart of estimated U.S. prescriptions per year, Glaucoma medicines (1900–2026). Carteolol enters in 1992 (estimated).
Principal riskSystemic beta blockade from eye drops
Legacy pregnancy categoryC
Defining liabilityBradycardia, hypotension and bronchospasm; overdose may cause conduction block or cardiogenic shock.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Elevated intraocular pressure / open-angle glaucoma | Adults | 1 drop affected eye(s) BID | 1 drop BID |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy Undefined
Lactation Undefined
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 1 % | drops | per unit | not offered |
Generic entry2000
Open Carteolol in the interactive console ↗